New cocktail of drugs and radiation targets Hard-to-Treat sarcoma
NCT ID NCT07205185
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of the immunotherapy epalrotokewali, chemotherapy eribulin, targeted therapy anlotinib, and radiotherapy in 46 people with advanced soft tissue sarcoma that has progressed after prior treatment. The goal is to see if this mix can shrink tumors or slow the disease. Researchers will monitor safety and how well patients respond.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Epalrotokewali (QL1706) plus eribulin, anlotinib, and radiotherapy
- What this could lead to
- If successful, this combination could offer a new treatment option for advanced soft tissue sarcoma that has stopped responding to standard therapies.
- What could go wrong
- This is an early phase 2 trial with only 46 participants, so results may not apply broadly. The combination also carries risks of serious side effects from the drugs and radiation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA (STS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Patient's own immune cells fight advanced sarcoma?
- Smartwatch exercise plan aims to rebuild fitness in young cancer survivors
- Can tailored exercise help young sarcoma survivors recover strength?
- Blood test aims to spot hidden cancer cells in 9 tumor types
- New drug combo aims to fight rare sarcoma
- Experimental vaccine fights sarcoma with Patient's own immune cells